期刊文献+

Beclin 1在乳腺浸润性导管癌组织中的表达 被引量:1

The Expression of Beclin 1 in Invasive Ductal Carcinoma of the Breast
下载PDF
导出
摘要 目的:探讨Beclin l在乳腺浸润性导管癌中的表达及临床意义。方法:免疫组织化学EnVision法、RT-PCR法和Western blot法检测50例乳腺浸润性导管癌及相应癌旁组织Beclin 1表达,分析其临床意义。结果:三种方法联合检测发现癌组织中Beclin 1阳性率低于癌旁组织,癌组织中Beclin 1相对表达量也低于癌旁组织;癌组织中Beclin 1表达与患者病理分级、临床分期和淋巴结转移情况有关(P<0.05),与患者年龄、绝经状况及乳头侵犯状况无关(P>0.05)。结论:Beclin l在乳腺浸润性导管癌中存在缺失表达或低表达,并与乳腺癌的发生、发展相关。 Objective:To investigate the expression of Beclin 1 in invasive ductal carcinoma ( IDC ) of the breast, and to evaluate the clinical implications.Method: Immunohistochemical, RT-PCR and Western blot methods were used to determine the expression of Beclin 1 in 50 cases of IDC and nearby mucosa of the carcinoma .The relationship between the gene expression and clinicopathological features were analyzed .Result:The lost and negative expression rates of Beclin 1 in IDC was higher than nearby mucosa of the carcinoma.The expression of Beclin 1 were negatively correlated with the clinicopathological features , tissue types and neck lymph node metastasis in IDC (P〈0.05), and no correlated with ages, menopausal status and nipple infringement status ( P〉0.05).Conclusion: There was a common lost and negative expression rates of Beclin 1 in IDC.The expression of Beclin 1 may relate to the tumorigenesis and development of the invasive ductal breast cancer .
出处 《河北医学》 CAS 2014年第7期1057-1061,共5页 Hebei Medicine
基金 广东省佛山市医学类科技攻关项目 (编号:201208135)
关键词 乳腺浸润性导管癌 BECLIN 1 免疫组织化学 RT-PCR WESTERN BLOT Invasive ductal carcinoma Beclin 1 Immunohistochemical RT-PCR Western blot
  • 相关文献

参考文献8

  • 1Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation [ J ]. Science, 2000,290 ( 5497 ) : 1717 - 1721.
  • 2Choi KS. Autophagy and cancer [ J ]. Exp Mol Med, 2012,44 (2) :109-120.
  • 3Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self- digestion [ J ]. Nature, 2008,451 ( 7182 ) : 1069-1075.
  • 4Meijer AJ, Codoguo P. Regulation arid role of autophagy in mammalian cells [ J ]. Int Biochem Cell Biol, 2004,36 (12) : 2445-2462.
  • 5Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mu- tations in primary breast and ovarian carcinomas [ J ]. Sci- ence, 1994,266(5182) : 120-122.
  • 6李捷,于观贞,王杰军,潘军,柳珂,李萍,周洲,陈颖.Beclin1和PTEN蛋白在胃癌中的表达及预后价值[J].中华消化杂志,2012,32(3):170-174. 被引量:8
  • 7陈波,金锋,姚凡,刘彩刚.乳腺癌中beclin1基因下调机制的研究[J].中国微生态学杂志,2009,21(12):1070-1072. 被引量:7
  • 8何新明,罗颖洁,杨通,莫明聪,林云恩,刘桂红.免疫组织化学染色技术常见问题的研究与探讨[J].中国免疫学杂志,2011,27(S1):1188-1190. 被引量:10

二级参考文献31

  • 1张惠球,刘奕生.免疫组织化学染色质量的影响因素[J].中国误诊学杂志,2006,6(3):571-573. 被引量:3
  • 2周小鸽.免疫组织化学染色的干扰因素及其处理[J].临床与实验病理学杂志,2006,22(4):389-392. 被引量:32
  • 3LIANG X H,KLEEMAN L K,JIANG H H,et al. Protection against fatal Sindbis virus encephalitis by Beclin, a novel Bcl-2 interacting protein[ J]. J Virol, 1998,72( 11 ) :8586-8596.
  • 4BOWLES E, CORSON T W, BAYANI J, et al. Profiling genomlc copynumber changes in retinoblastoma beyond loss of RB1 [ J]. Gene Chromosomes Cancer,2007,46 (2) : 118 -129.
  • 5DAI Q, DEUBLER D A, MAXWELL T M, et al. A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1 [J]. Genomics,2001,71 (3) :324-329.
  • 6LALLAS T A,BEUKERS A E,BULLER R E. BRCA1 mutations in familial ovarian cancer[ J ]. Molecul Genet Metabol, 1999,67 ( 4 ) : 357- 363.
  • 7SOURVINOS G, KIARIS H, TSIKKINIS A, et al. Microsatellite instability and loss of heterozygosity in primary breast tumours [ J ]. Tumour Biol, 1997,18 ( 3 ) : 157-166.
  • 8YUE Z, JIN S,YANG C, et al. Beclin 1 ,an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor [J]. PNAS USA ,2003,100 (25) : 15077-15082.
  • 9AITA V M,LIANG X H,MURTY V V ,et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21 [ J]. Genomics, 1999,59( 1 ) :59-65.
  • 10WELCSH P L,OWENS K N,KING M C. Insights into the functions of BRCA1 and BRCA2[J]. Trends in Genetics,2000,16(2) :69-74.

共引文献22

同被引文献13

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部